Exposure-Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

• Main Authors: Joachim Grevel (Author), Garrit Jentsch (Author), Rupert Austin (Author), Nicolaas H. Prins (Author), John Lettieri (Author), David Mitchell (Author), Funan Huang (Author), Marcia S. Brose (Author), Martin Schlumberger (Author), Gerold Meinhardt (Author), Carol E. A. Peña (Author), Bart A. Ploeger (Author)
• Format: Book
• Published: Wiley, 2019-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the incidence of some adverse events (AEs) were higher tha...